GLOW is a name for a vial, not a name for a molecule. Three separate peptides are freeze-dried into it: GHK-Cu, a three-residue copper complex; BPC-157, a fifteen-residue sequence; and TB-500, an acetylated seven-residue fragment. Sellers' labels state them at 50 mg, 10 mg and 10 mg.
That is where most writing about the blend begins and ends — the recipe. This entry does the other thing, which is to read what the public record holds for each of the three, one record at a time. It is a short read, and the shortness is the finding.
The registry picture, component by component
On 2026-09-19 the three compounds had eight registered studies between them. Counting stops there; reading does not.
GHK-Cu — three registrations, one of which administers it.
- NCT07437586 applies a GHK-Cu topical gel to standardised punch-biopsy wounds against a vehicle gel. Recruiting; no results posted. This is the only registration in the set that gives GHK-Cu to a person.
- NCT07706361 applies an adhesive patch and measures circulating GHK as an outcome. The peptide here is something being counted, not something being given. Not yet recruiting.
- NCT05932732 is a facial-treatment device study — a HydraFacial system, with a topical product among the interventions. Completed, no results posted.
The route is worth stating plainly. The one study that administers GHK-Cu puts it on skin, as a gel, onto an open biopsy wound. A lyophilised vial is not that, and a topical wound-healing result does not transfer to it.
BPC-157 — four registrations, none with results.
- NCT07803250, BPC-157 after rotator cuff repair surgery, against a sham. Not yet recruiting.
- NCT07437547, BPC-157 for acute hamstring strain, against placebo. Recruiting.
- NCT02637284, filed in 2015 under the product name Bepecin as a safety and pharmacokinetics trial. Its registry status is UNKNOWN, which the registry applies when a sponsor has not updated a record within the expected interval.
- NCT07752381 administers "Parlay Recover Peptide Gummies" — a consumer product, not BPC-157 as such. Marked completed, no results posted.
So of the four, two have not begun, one has gone quiet since 2015, and the completed one gave a gummy.
TB-500 — one registration. NCT07487363 studies TB-500 against placebo for cardiovascular biomarkers. Recruiting, no results. Nothing about tendon, muscle or wound repair — the uses the blend is sold for.
None of the eight has posted a result.
The literature is large and the clinical literature is empty
BPC-157 had 230 PubMed records on 2026-09-19. That is a substantial body of work, and it is almost entirely preclinical: zero of those 230 carry the clinical-trial publication type. GHK-Cu had 180 records on the same date.
This is the gap that makes the compound hard to read about honestly. A reader who sees "hundreds of studies" is seeing a real number attached to the wrong question. The number counts papers; it does not count trials, and on this compound the two figures are 230 and 0.
What this entry does not cover
Whether sellers agree on the recipe, how much copper is in the vial, and what the formulation questions are — those are counted in PeptideGlowJournal's glow-blend label census, and are not restated here.
The four-component version of the same vial, and the arithmetic of what fraction of the molecules each ingredient really supplies, is in this library's KLOW entry. The short version is that the component the blend is least sold for is the one there is most of.
Where it stands
Neither the mixture nor any of the three components is an approved medicine in the United States. Material sold under these names carries a research-use label — a statement by the seller about what the product is sold for, not an evaluation by anyone.
What would change the picture is straightforward and checkable: a posted result on any one of those eight records. As of 2026-09-19 there are none.
Related entries in this library: the copper tripeptide, the fifteen-residue repair peptide, the acetylated heptapeptide, KLOW, and the Wolverine stack, which pairs the latter two without the copper peptide.